Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 109-120 of 212 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 109-120 of 212 studies
-
Restore CFTR ProteinCompleted with Results
VX-661 alone and in combination with ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-101This study looked at the safety and effectiveness of multiple dose levels of VX-661 alone and in combination with ivacaftor (Kalydeco®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
9
-
Length of Participation:
84 days
-
-
Restore CFTR ProteinCompleted with Results
VX-770 Expanded Access Program , protocol number Vertex VX11-770-901This open-label expanded access program (EAP) study was designed to provide ivacaftor to patients in critical medical need prior to commercial product availability.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
Less than 40%
-
Number of Visits:
1
-
Length of Participation:
9 months
-
-
Restore CFTR ProteinCompleted with Results
Vertex 770 - a phase 2 trial evaluating the effect of VX- 770 on Lung Clearance Index , protocol number Vertex VX10-770-106This trial studied the effect of VX-770 (ivacaftor) on lung clearance index in people with CF ages 6 years and older with the G551D mutation and an FEV1 >90%.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
90% or greater
-
Number of Visits:
8
-
Length of Participation:
19 weeks
-
-
Restore CFTR ProteinCompleted with Results
VX-770 in People with CF and G551D Mutation - Open Label Safety Study (PERSIST) , protocol number Vertex VX-770-105This study looked at the long-term safety of ivacaftor in people with CF and the G551D mutation. Subjects received ivacaftor for 96 weeks during this study.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
10
-
Length of Participation:
2 years
-
-
Restore CFTR ProteinCompleted with Results
VX-770 Phase 2 study in People with CF and Genotype G551D , protocol number Vertex VX06-770-101This Phase 2 clinical study looked at the safety and tolerability of ivacaftor (VX-770) in people with CF and at least one allele with the G551D CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
56 days
-
-
Restore CFTR ProteinCompleted with Results
Vertex-770 in People with CF with Homozygous Delta F508 Mutation (DISCOVER) , protocol number Vertex 770-104This study looked at the safety and effectiveness of VX-770 (ivacaftor), in people with Cystic Fibrosis (CF) age 12 years and older, with homozygous Delta F508 mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
22 weeks
-
-
Restore CFTR ProteinCompleted with Results
Vertex-770 and the G551D mutation (STRIVE) , protocol number Vertex VX08-770-102This phase 3 study looked at the safety and effectiveness of ivacaftor (VX-770) in adolescents and adults with CF and the G551D mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
54 weeks
-
-
Restore CFTR ProteinCompleted with Results
Vertex 770 in Children with CF and the G551 Mutation (ENVISION) , protocol number Vertex VX08-770-103This phase 3 study looked at the safety and effectiveness of ivacaftor (VX-770) in people with CF aged 6 to 11 years with the G551D mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
54 weeks
-
-
Restore CFTR ProteinCompleted with Results
Ataluren (PTC 124) in Cystic Fibrosis , protocol number PTC124-GD-009-CFThis trial looked at the effectiveness and safety of ataluren in people with CF who have a nonsense mutation of cystic fibrosis.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
15
-
Length of Participation:
48 weeks
-
-
Restore CFTR ProteinCompleted with Results
Safety Study of VX 809 in People with CF and Homozygous for Delta F508 Gene Mutation , protocol number Vertex VX08-809-101The purpose of this study was to evaluate the safety and tolerability, of lumacaftor (VX-809) in subjects with cystic fibrosis who have two copies of the F508del CFTR gene mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
31 days
-
-
Mucociliary ClearanceCompleted with Results
BALANCE-CF 1: Study of BI 1265162, a mucus clearance drug, in teens and adults with CF , protocol number BI-1399-0003This study evaluated the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
7 weeks
-
-
Mucociliary ClearanceCompleted with Results
SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002This study took place in Europe, Australia and the U.S. It evaluated the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in preschool children with CF.
-
Age:
3 Years to 5 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
6
-
Length of Participation:
54 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More